The Lancet Respiratory Medicine· David E Gerber, Yating Wang, Corey J Langer, Onkar V Khullar, David E Kozono, Lala A Cornelius, Patrick M Forde, Matthew O Nwaneri, Joel W Neal, Ashita Talsania, Ticiana A Leal, Malini Patel, Kavitha R Donthireddy, Saiama N Waqar, Jamie E Chaft, Ramaswamy Govindan, Jacob M Sands, Shakun Malik, Tianhong Li, Zhuoxin Sun, Thomas E Stinchcombe, Everett E Vokes, Sumithra J Mandrekar, Geoffrey R Oxnard, David P Carbone, Suresh S Ramalingam·· 2026-08-26精选AI 评分70
E4512三期试验:克唑替尼未能延长早期ALK阳性非小细胞肺癌患者术后无复生存期
[Articles] Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial
AI 导读
这项名为E4512的三期随机对照试验显示,克唑替尼作为辅助治疗并不能延长已手术切除的早期ALK阳性非小细胞肺癌患者的无复生存期。基于此结果,研究团队建议不推荐在ALK阳性非小细胞肺癌切除术后使用克唑替尼进行辅助治疗。
推荐理由
该三期试验结果明确否定了克唑替尼在ALK阳性NSCLC术后的辅助治疗价值,为临床决策提供了直接依据。
来源:The Lancet Respiratory Medicine · thelancet.com